Described embodiments include an apparatus (20, 21), which includes a support (22), including an outer surface (24) and configured for insertion into a body of a subject. The apparatus further includes multiple atoms (26) of a radionuclide, which radioactively decays to produce a daughter radionuclide, coupled to the outer surface, and a layer (28, 33) of a polymer, which is permeable to the daughter radionuclide, that covers the atoms. Other embodiments are also described.

A dual double balloon catheter includes a catheter having a proximal end portion, a central portion and a distal end portion, and a secondary treatment balloon for a catheter. The catheter includes a plurality of lumens within the catheter extending from the proximal end portion, a plurality of inflatable balloons positioned in the central portion and a secondary treatment balloon communicatively associated with the distal end portion of the catheter, and the balloons and the secondary treatment balloon being communicatively connected with a corresponding one of the plurality of lumens to selectively inflate/deflate the corresponding inflatable balloon or to receive a radioactive dose or a therapeutic agent for a treatment.

An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.

A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.

A method for making a radiopharmaceutical cold kit without lyophilization, comprising (1) providing a labeling ligand, a reducing agent, and a bulking agent, and at least one of an antioxidant and an exchange ligand, wherein each of said labeling ligand, reducing agent, bulking agent, antioxidant and exchange ligand is provided in a dry form; and (2) combining and mixing the labeling ligand, the reducing agent, the bulking agent, and at least one of the antioxidant and the exchange ligand to produce a dry powder mixture, wherein the wherein the dry powder mixture is produced without the use of a lyophilization step. The radiopharmaceutical cold kit comprising the dry powder mixture may be stored, or combined with a radionuclide such as Technetium-99m (.sup.99mTc).

A device and method for radioembolization in the treatment of cancer cells in the body. In preferred embodiments, a radiomicrosphere is formed from a resin where an alpha emitting isotope is used for tumoricidal purposes. As the alpha emitter decays, daughters of the alpha decay are captured by the resin. In accordance with the preferred embodiments, the resin is polyfunctional where the resin has at least three different types of functional groups for cation binding. In preferred embodiments, the three functional groups bonded to the resin include a carboxylic acid group, a diphosphonic acid group, and a sulfonic acid group. In further embodiments, the device comprises at least two isotopes; wherein a first isotope is for therapeutic purposes and a second isotope is for dosimetric purposes. The second isotope is a positron emitter for PET based dosimetry. In preferred embodiments, a post-treatment radiation absorbed dose is determined using the present invention, allowing both treatment and treatment efficacy to be provided to a cancer patient.

The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

Methods of performing targeted alpha therapy of a cancer patient utilizing actinium-225, methods of preparing a targeted alpha therapy drug that includes actinium-225, methods of preparing actinium-225 from radium-226, and methods of recovering radium-226 from an aqueous produced material stream generated from a natural resource extraction process. The methods of recovering radium-226 include separating the radium-226 from the produced material stream to generate recovered radium-226. The methods of preparing actinium-225 include converting the recovered radium-226 into actinium-225. The methods of preparing the targeted alpha therapy drug include incorporating the actinium-225 into the targeted alpha therapy drug. The methods of performing targeted alpha therapy include treating the cancer patient with the targeted alpha therapy drug.

This disclosure provides design, material, preparation methods, and use alternatives for medical devices. An example method of preparing a stent comprises applying a coating to a portion of the stent at a medical treatment facility, the coating including a plurality of radioactive elements and a substrate. The plurality of radioactive elements are mixed with the substrate to form a mixture such that the plurality of radioactive elements are dispersed within the substrate prior to the coating being applied on the stent.

Embodiments of the present disclosure are directed to a phototherapy eye device. In an example, the phototherapy eye device includes a number of radioluminescent light sources and an anchor. Each radioluminescent light source includes an interior chamber coated with phosphor material, such as zinc sulfide, and containing a radioisotope material, such as gaseous tritium. The volume, shape, phosphor material, and radioisotope material are selected for emission of light at a particular wavelength and delivering a particular irradiance on the retina (when implanted in an eyeball). The wavelength is in the range of 400 to 600 nm and the irradiance is substantially 10.sup.9 to 10.sup.11 photons per second per cm.sup.2.